Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301

News

Showing posts for — Author: kioradev

04.01.21

EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, MA, April 01, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it...
03.25.21

EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update

WALTHAM, MA, March 25, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a...
02.01.21

EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation

- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -   - Stephen From Elevated from Chief Executive Officer to Executive Chairman -  WALTHAM, MA, February...
01.06.21

EyeGate Enters Into Agreement for $8.0 Million Private Placement

WALTHAM, MA, January 06, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the...
12.21.20

EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma

WALTHAM, MA, December 21, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical stage company focused on developing products for treating disorders of the eye,...
11.09.20

EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, November 9, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
09.08.20

EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference

WALTHAM, MA, September 8th, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
08.12.20

EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product

WALTHAM, MA, August 12, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...